Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-deamino-1-monocarba-2-(tyr(ome))-oxytocin
2. Dcomot
3. Depotocin
4. Oxytocin, 1-desamino-1-monocarba-(tyr(ome))(2)-
5. Oxytocin, 1-desamino-1-monocarba-(tyrosine(o-methyl))(2)-
1. 37025-55-1
2. Pabal
3. Carbetocino
4. Carbetocinum
5. Chebi:59204
6. Lv-101
7. Carbetocinum [inn-latin]
8. Carbetocino [inn-spanish]
9. Deamino-2-o-methyltyrosine-1-carbaoxytocin
10. 1-butyric Acid-2-(3-(p-methoxyphenyl)-l-alanine)oxytocin
11. 88twf8015y
12. 1-butanoic Acid-2-(o-methyl-l-tyrosine)-1-carbaoxytocin
13. Fe 992097
14. Fe-992097
15. 7-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
16. C45h69n11o12s
17. (2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,1
18. Carbetocin [mi]
19. Carbetocin [inn]
20. Carbetocin [usan]
21. Carbetocin [mart.]
22. Carbetocin [who-dd]
23. Schembl39224
24. Carbetocin [usan:inn:ban]
25. Unii-88twf8015y
26. Chembl3301668
27. Gtpl11169
28. Dtxsid90897527
29. 1-carbaoxytocin, 1-butanoic Acid-2-(o-methyl-l-tyrosine)-
30. (2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide
31. Who 5014
32. Einecs 253-312-6
33. Bdbm50044677
34. Mfcd01076600
35. Akos015994647
36. Zinc150338703
37. Db01282
38. Hs-2007
39. Ncgc00485451-02
40. Hy-17573
41. 025c551
42. A823503
43. Carbetocin 100 Microg/ml In Acetonitrile:methanol
44. Q5037853
45. 1-buttersaeure-2-(3-(4-methoxyphenyl)-l-alanin)oxytocin
46. 1-carboxytocin, 1-butanoic Acid-2-(o-methyl-l-tyrosine)-
47. Ethyl?2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxylate
48. (2s)-2-{[(2s)-1-{[(3r,6s,9s,12s,15s)-12-[(2s)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}pyrrolidin-2-yl]formamido}-n-(carbamoylmethyl)-4-methylpentanamide
49. 1-[6-(2-amino-2-oxo-ethyl)-9-(3-amino-3-oxo-propyl)-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-12-sec-butyl-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]-n-[1-[(2-amino-2-oxo-ethyl)carbamoyl]-3-methyl-butyl]pyrrolidine-2-carboxamide; 2,2,2-t;carbetocin
50. 1-{[(3r,6s,9s,12s,15s)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2s)-butan-2-yl]-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-l-prolyl-l-leucylglycinamide
51. Glycinamide, N-(4-mercapto-1-oxobutyl)-o-methyl-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucyl-, Cyclic (1->5)-thioether
52. O-methyl-n-(4-sulfanylbutanoyl)-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucyl-glycinamide Cyclic (1->5)-thioether
Molecular Weight | 988.2 g/mol |
---|---|
Molecular Formula | C45H69N11O12S |
XLogP3 | -1.1 |
Hydrogen Bond Donor Count | 10 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 18 |
Exact Mass | 987.48478785 g/mol |
Monoisotopic Mass | 987.48478785 g/mol |
Topological Polar Surface Area | 388 Ų |
Heavy Atom Count | 69 |
Formal Charge | 0 |
Complexity | 1850 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used to control postpartum hemorrhage and bleeding after giving birth.
Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is sold under the trade name Duratocin. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the uterus.
Delayed-Action Preparations
Dosage forms of a drug that act over a period of time by controlled-release processes or technology. (See all compounds classified as Delayed-Action Preparations.)
Oxytocics
Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) (See all compounds classified as Oxytocics.)
H - Systemic hormonal preparations, excl. sex hormones and insulins
H01 - Pituitary and hypothalamic hormones and analogues
H01B - Posterior pituitary lobe hormones
H01BB - Oxytocin and analogues
H01BB03 - Carbetocin
Absorption
Bioavailability is 80% following intramuscular injection.
40 minutes
Carbetocin binds to oxytocin receptors present on the smooth musculature of the uterus, resulting in rhythmic contractions of the uterus, increased frequency of existing contractions, and increased uterine tone. The oxytocin receptor content of the uterus is very low in the non-pregnant state, and increases during pregnancy, reaching a peak at the time of delivery.
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39953
Submission : 2024-05-29
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2019-01-17
Registration Number : 20190117-210-J-164
Manufacturer Name : BCN Peptides SA
Manufacturer Address : Pol. Ind. Els Vinyets-Els Fogars, II, 08777 Sant Quinti de Mediona, Barcelona Spain
Date of Issue : 2019-09-03
Valid Till : 2022-09-02
Written Confirmation Number : WC-0237
Address of the Firm :
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39953
Submission : 2024-05-29
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Carbetocin Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carbetocin Acetate, including repackagers and relabelers. The FDA regulates Carbetocin Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carbetocin Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carbetocin Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carbetocin Acetate supplier is an individual or a company that provides Carbetocin Acetate active pharmaceutical ingredient (API) or Carbetocin Acetate finished formulations upon request. The Carbetocin Acetate suppliers may include Carbetocin Acetate API manufacturers, exporters, distributors and traders.
click here to find a list of Carbetocin Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carbetocin Acetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Carbetocin Acetate active pharmaceutical ingredient (API) in detail. Different forms of Carbetocin Acetate DMFs exist exist since differing nations have different regulations, such as Carbetocin Acetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carbetocin Acetate DMF submitted to regulatory agencies in the US is known as a USDMF. Carbetocin Acetate USDMF includes data on Carbetocin Acetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carbetocin Acetate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carbetocin Acetate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carbetocin Acetate Drug Master File in Korea (Carbetocin Acetate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carbetocin Acetate. The MFDS reviews the Carbetocin Acetate KDMF as part of the drug registration process and uses the information provided in the Carbetocin Acetate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carbetocin Acetate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carbetocin Acetate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carbetocin Acetate suppliers with KDMF on PharmaCompass.
A Carbetocin Acetate written confirmation (Carbetocin Acetate WC) is an official document issued by a regulatory agency to a Carbetocin Acetate manufacturer, verifying that the manufacturing facility of a Carbetocin Acetate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carbetocin Acetate APIs or Carbetocin Acetate finished pharmaceutical products to another nation, regulatory agencies frequently require a Carbetocin Acetate WC (written confirmation) as part of the regulatory process.
click here to find a list of Carbetocin Acetate suppliers with Written Confirmation (WC) on PharmaCompass.
Carbetocin Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carbetocin Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carbetocin Acetate GMP manufacturer or Carbetocin Acetate GMP API supplier for your needs.
A Carbetocin Acetate CoA (Certificate of Analysis) is a formal document that attests to Carbetocin Acetate's compliance with Carbetocin Acetate specifications and serves as a tool for batch-level quality control.
Carbetocin Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Carbetocin Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carbetocin Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Carbetocin Acetate EP), Carbetocin Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carbetocin Acetate USP).
LOOKING FOR A SUPPLIER?